Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

0.9188
+0.00630.69%
Volume:26.61K
Turnover:24.43K
Market Cap:25.71M
PE:-0.23
High:0.9500
Open:0.9500
Low:0.8953
Close:0.9125
52wk High:7.19
52wk Low:0.6230
Shares:27.98M
Float Shares:22.81M
Volume Ratio:1.31
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9545
EPS(LYR):-3.9545
ROE:-230.31%
ROA:-88.16%
PB:6.19
PE(LYR):-0.23

Loading ...

Jasper Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
May 08

Jasper Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Apr 02

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

TIPRANKS
·
Apr 01

Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate

Benzinga
·
Mar 31

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

TIPRANKS
·
Mar 31

Jasper Therapeutics Q4 EPS USD -0.32

THOMSON REUTERS
·
Mar 31

Jasper Therapeutics FY25 net loss narrows to $75.8 million; cash drops to $28.7 million

Reuters
·
Mar 31

Press Release: Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 31

Jasper Therapeutics Inc : UBS Assumes Coverage With Neutral Rating; Target Price $1.5

THOMSON REUTERS
·
Mar 23

UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25

MT Newswires Live
·
Mar 23

Jasper Therapeutics Coverage Assumed by UBS at Neutral

Dow Jones
·
Mar 23

Jasper Therapeutics Inc. Publishes Corporate Presentation on Briquilimab Mast Cell Depletion Programs in Chronic Urticaria and Asthma

Reuters
·
Mar 02

Jasper Therapeutics to Present at TD Cowen Healthcare Conference

Reuters
·
Feb 25

Jasper Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Reuters
·
Feb 23

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jan 14

Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases

Reuters
·
Jan 13

Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating

TIPRANKS
·
Jan 09

Jasper Therapeutics Reports Positive Updated Data From Briquilimab Studies in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
Jan 08

Jasper Therapeutics Reports Positive Briquilimab Data in Chronic Spontaneous Urticaria Study

Reuters
·
Jan 08

BRIEF-Jasper Therapeutics Appoints Jeet Mahal As Chief Executive Officer To Lead Next Phase Of Clinical Growth

Reuters
·
Jan 08